stars 1 stars 2 stars 3

Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc. Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and peptides.

Adjuvatis Questions

The Adjuvatis annual revenue was $5 million in 2026.

Camille Ayad is the Chief Scientific Officer of Adjuvatis.

1 people are employed at Adjuvatis.

Adjuvatis is based in Lyon, Auvergne-Rhône-Alpes.

The NAICS codes for Adjuvatis are [32541, 3254, 32, 325].

The SIC codes for Adjuvatis are [283, 28].

Top Adjuvatis Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users